Keyphrases
Acute Myeloid Leukemia
49%
Adverse Events
17%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
45%
Apoptosis
10%
Bone Marrow
21%
Bortezomib
12%
Breast Cancer
38%
Brentuximab Vedotin
13%
Cancer Types
11%
Carboplatin
10%
Chemotherapy
49%
Chimeric Antigen Receptor T Cells (CAR-T)
13%
Cisplatin
12%
Clinical Outcomes
17%
Clinical Trials
28%
Clonal Hematopoiesis
10%
Colorectal Cancer
12%
Complete Remission
11%
Complete Response
14%
Confidence Interval
41%
Cyclophosphamide
14%
Diffuse Large B-cell Lymphoma (DLBCL)
17%
Disease Progression
12%
Docetaxel
12%
Doxorubicin
16%
Follicular Lymphoma
16%
Gemcitabine
14%
Gene Expression
15%
Glioblastoma
10%
Graft-versus-host Disease (GvHD)
25%
Granulocyte Colony-stimulating Factor (G-CSF)
29%
Hazard Ratio
21%
Hematological Malignancies
13%
Hematopoietic Cell Transplantation
12%
Hematopoietic Stem Cells
28%
High Risk
14%
Hodgkin Lymphoma
12%
Human Epidermal Growth Factor Receptor 2 (HER2)
12%
Human Immunodeficiency Virus Type 1 (HIV-1)
19%
Human T-cell Leukemia Virus Type 1 (HTLV-1)
21%
In Cancer
28%
Lenalidomide
13%
Leukemia
24%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
14%
Lung Cancer
17%
Lymphoma
16%
Macrophages
14%
Malignancy
12%
Mantle Cell Lymphoma
17%
Median Overall Survival
13%
Median Progression-free Survival
11%
Melanoma
12%
Metastasis
10%
Metastatic Breast Cancer
18%
Monotherapy
11%
Mouse Model
11%
Multiple Myeloma
39%
Myelodysplastic Syndrome
18%
Natural Killer Cells
25%
NCCN Guidelines
16%
Neutropenia
11%
Newly Diagnosed
11%
Next-generation Sequencing
11%
Non-Hodgkin Lymphoma
18%
Non-small Cell Lung Cancer (NSCLC)
34%
Older Adults
15%
Older Patients
12%
Oncology
14%
Overall Response Rate
15%
Overall Survival
61%
Paclitaxel
11%
Pancreatic Cancer
15%
Pancreatic Ductal Adenocarcinoma
12%
Partial Response
14%
Pembrolizumab
10%
Phase I Study
12%
Phase II Study
44%
Phase II Trial
35%
Placebo
13%
Previously Treated
10%
Programmed Death-ligand 1 (PD-L1)
13%
Progression-free Survival
36%
Prostate Cancer
12%
Radiation Therapy
14%
Randomized Phase II Trial
10%
Relapsed or Refractory
31%
Relapsed or Refractory multiple Myeloma
10%
Response Rate
11%
Rituximab
23%
Solid Tumors
14%
Somatic mutation
11%
T Cells
28%
Targeted Therapy
19%
Transplantation
11%
Triple-negative Breast Cancer
14%
Tumor
76%
Tumor Cells
14%
Tumor Growth
10%
Tumor Microenvironment
10%
Virus
10%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
8%
Acute Myeloid Leukemia
33%
Adverse Event
21%
Arm
20%
B Cell
11%
B-Cell Chronic Lymphocytic Leukemia
8%
Biological Marker
18%
Bortezomib
7%
Breast Cancer
56%
Brentuximab Vedotin
9%
Cancer
32%
Cancer Cell
11%
Cancer Therapy
10%
Cell Transplantation
21%
Chemoradiotherapy
8%
Chimeric Antigen Receptor T-Cell
7%
Circulating Tumor DNA
7%
Cisplatin
9%
Clinical Trial
32%
Colorectal Carcinoma
9%
Connective Tissue Cancer
10%
Cyclophosphamide
9%
Diagnosis
9%
Diffuse Large B-Cell Lymphoma
15%
Disease Free Survival
7%
Diseases
74%
Doxorubicin
10%
Drug Megadose
8%
Epidermal Growth Factor Receptor
7%
Follicular Lymphoma
11%
Gemcitabine
8%
Gene Expression
7%
Glioblastoma
7%
Graft Versus Host Reaction
7%
Granulocyte Colony Stimulating Factor
10%
Hazard Ratio
16%
Health Care Cost
7%
Hematologic Malignancy
8%
Hematopoiesis
10%
Hematopoietic Cell
40%
Hematopoietic Stem Cell Transplantation
7%
Hodgkin's Lymphoma
16%
Hormone Therapy
8%
Human Immunodeficiency Virus
11%
Immune Checkpoint Inhibitor
7%
Immunity
13%
Immunotherapy
24%
In Vitro
9%
Infection
8%
Lenalidomide
9%
Leukemia
16%
Lung Cancer
20%
Macrophage
8%
Malignant Neoplasm
67%
Mantle Cell Lymphoma
14%
Melanoma
15%
Meta-Analysis
7%
Metastatic Breast Cancer
12%
Metastatic Carcinoma
24%
Multiple Myeloma
37%
Myelodysplastic Syndrome
14%
Myeloma
7%
Natural Killer Cell
8%
Neoplasm
100%
Neutropenia
8%
Next Generation Sequencing
7%
Non Small Cell Lung Cancer
30%
Non-Hodgkin Lymphoma
19%
Oncology
29%
Overall Survival
61%
Paclitaxel
9%
Pancreas Adenocarcinoma
12%
Pancreas Cancer
13%
Pembrolizumab
9%
Peripheral T-Cell Lymphoma
7%
Phase II Trials
10%
Placebo
10%
Positron Emission Tomography
9%
Progression Free Survival
35%
Prostate Cancer
15%
Quality of Life
9%
Radiation Therapy
22%
Receptor
8%
Recurrent Disease
15%
Rituximab
19%
Small Cell Lung Cancer
8%
Soft Tissue Sarcoma
7%
Solid Malignant Neoplasm
11%
Stem Cell
10%
Stem Cell Transplant
8%
Surgery
14%
Systematic Review
8%
Systemic Therapy
9%
T Cell
24%
Targeted Therapy
18%
Transplantation
21%
Triple Negative Breast Cancer
10%
Tumor Cell
10%
Tumor Progression
11%
Xenograft
7%